SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors express significant frustration and skepticism toward the Board's decision to accept an all-cash acquisition offer, which many feel drastically undervalues the company's cash position, core drug assets, and future growth potential. The community is actively debating the merits of the deal, with some shareholders organizing to oppose the tender offer and others seeking legal avenues to challenge what they characterize as an unethical 'fire sale' by management.

MMTec, Inc. engages in the holding of an equity interest in MM Future. It operates through the Gujia, MM Future and HC Securities and MM Global. The Gujia, MM Future and HC Securities segment provide market data services and consulting services. The MM Global segment is involved in introducing a broker that clears all transactions through a clearing broker dealer and earns commission income, placement agent services fee, and other related income from customers. The company was founded on January 4, 2018 and is headquartered in Hong Kong.

Mmtec Inc

Mmtec Inc is generating significant market interest as traders speculate on potential short squeeze dynamics and the company's efforts to maintain its NASDAQ listing status. Community discussions are heavily focused on the stock's extreme volatility and its tendency to mirror past microcap momentum plays, with participants actively debating the risks of delisting against the possibility of aggressive rallies.

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation–based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company’s offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

YD Bio Ltd.

YDES is currently garnering significant attention from retail traders due to its status as a recent Nasdaq uplisting with a remarkably low float, leading to discussions about potential volatility and short-squeeze setups. The community is closely monitoring the stock's price action alongside its associated warrants, debating whether current valuations present a mispricing opportunity or a speculative trap.

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

LENSAR Inc

LENSAR Inc. shares are under significant pressure following the mutual termination of its merger agreement with Alcon, a decision prompted by mounting regulatory opposition from the FTC. The community is actively debating the company's standalone future, weighing concerns over operational liquidity and intense market competition against the potential durability of its recurring revenue model and ALLY system adoption.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending due to its unique 'PvE' (Player-versus-Environment) narrative, which emphasizes long-term community conviction over short-term speculative trading. Supporters are actively highlighting the project's 'Airlock' mechanismwhere nearly half of the supply is voluntarily lockedas proof of a committed, cult-like movement that is actively outperforming typical market volatility.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics is seeing intense retail interest as investors focus on its role as a specialized supplier for U.S. defense programs and high-growth AI infrastructure. The community is actively debating the stock's low float and strong insider ownership, with many monitoring for potential momentum breakouts tied to ongoing government contract announcements.

Ethereum Classic

Ethereum Classic is experiencing renewed community focus as investors speculate on a long-awaited breakout, with many sentiment-driven discussions highlighting the contrast between the token's historical performance and its current suppressed price action. Traders are actively debating the timing of a potential trend reversal, frequently citing broader crypto market catalysts and comparing its utility to other established proof-of-work assets.

WorldFinancial

WLFI is currently facing significant volatility and intense community debate as investors react to congressional scrutiny regarding the project's foreign investment ties and its relationship with the Trump administration. While some participants view the current price action as a strategic accumulation opportunity ahead of upcoming industry forums, others express concern over token dilution, governance transparency, and the potential for the project to follow the downward trajectory of past politically-linked assets.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is experiencing significant momentum and investor interest following its listing on major brokerage platforms and the launch of new institutional-grade DeFi features. Community members are actively debating its potential as a primary competitor to traditional exchanges, with many focusing on its deep liquidity, high-volume perpetual trading, and aggressive token buyback programs as key drivers for long-term growth.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a long-standing satirical project that has transitioned onto the Solana network, with the community positioning it as a cultural successor to early Bitcoin lore. Supporters are actively discussing its 15-year history and perceived potential for generational wealth, while debates continue between those dismissing it as a meme-driven joke and those convinced it represents a unique opportunity in the current market cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,800 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 1,800 shares of the company's stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $15.00, for a total value of $27,000.00. Following the completion of the sale, the chief...

Thomas Catinazzo Sells 1,800 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock in a transaction dated Thursday, April 9th. The shares were sold at an...

Relay Therapeutics (NASDAQ:RLAY) CFO Sells $230,498.17 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock in a transaction dated Tuesday, April 7th. The shares were sold at an...

Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week High on Analyst Upgrade

Relay Therapeutics (NASDAQ:RLAY) Reaches New 12-Month High After Analyst Upgrade...

Relay Therapeutics (NASDAQ:RLAY) Given New $21.00 Price Target at Barclays

Barclays lifted their price objective on shares of Relay Therapeutics from $17.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday...

JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. $RLAY

JPMorgan Chase & Co. cut its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 89.3% during the 3rd quarter, according to its most recent Form 13F filing with the...

Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?

Relay Therapeutics (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

SG Americas Securities LLC Acquires 189,004 Shares of Relay Therapeutics, Inc. $RLAY

SG Americas Securities LLC increased its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 591.7% during the fourth quarter, according to the company in its most recent...

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat...

Relay Therapeutics (NASDAQ:RLAY) Reaches New 52-Week High  - Time to Buy?

Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High - Still a Buy...

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Current Price	$14.94
Prev Close	$15.00
Open	$15.00
Dividend Yield	0.00%
50-Day Moving Average	$9.97
Beta	1.87
Avg. Volume	2.6M
PE Ratio	-9.26

52-Week High	$15.42
52-Week Low	$2.30
Market Capitalization	$2.68B
EPS (Annual)	-$1.61
Price to Book	4.58
Revenue Per Employee	$79,973.96

RLAY
Relay Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RLAY News

RLAYRelay Therapeutics Inc